A novel copper chelator for the suppression of colorectal cancer. Issue 2 (19th January 2023)

• Record Type: Journal Article
• Authors: Shi, Xiaolong; Li, Ying; Jia, Mengting; Zhang, Zhixin; Huang, Lunhua; Zhang, Miaomiao; Xun, Qingqing; Jiang, Di; Liu, Yanrong
• Is Part Of: Drug development research. Volume 84:Issue 2(2023)
• Page Start: 312
• Page End: 325
• Publication Date: 2023-01-19
• Subjects: colorectal cancer -- copper chelator -- thieno[3, 2‐c]pyridine; Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.22034
• Languages: English
• ISSNs: 0272-4391

Abstract

Abstract: Copper ions play a crucial role in the progression of cancers. Tumor tissue is rich in copper ions, and copper chelators could potentially scavenge these copper ions and thus exert an antitumor effect. In this study, we report the synthesis of a novel thieno[3, 2‐ c ]pyridine compound we have called "JYFY‐001 " that can act as the copper chelator thanks to the inclusion of an N ‐(pyridin‐2‐yl)acetamide moiety that targets copper ions. JYFY‐001 potently inhibited cancer proliferation, inducing cell apoptosis and impairing the extracellular acidification rate and oxygen consumption rate of colorectal cancer (CRC) cells. JYFY‐001 also inhibited the growth of a CRC‐transplanted tumor in a dose‐dependent manner, inducing apoptosis of the tumor cells and promoting the infiltration of lymphocytes in the CRC‐transplanted tumor tissues. JYFY‐001 also enhanced the antitumor effects of the programmed cell death protein 1 (PD‐1) inhibitor. The relatively benign nature of JYFY‐001 was demonstrated by the effect on normal cell viability and acute toxicity tests in mice. Our findings suggest that JYFY‐001 is a prospective copper chelator to be used as a targeted drug and a synergist of immunotherapy for CRC treatments.